Cancer is never a single disease. Within any tumor type, oncologists have long recognized distinct molecular subtypes that ...
Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still ...
WEST PALM BEACH — There is no shortage of efforts to subtype multiple sclerosis (MS) using data from imaging, molecular activity, genetics, epigenetics, and other factors. However, there is ongoing ...
Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted ...
Cell lines are an important in vitro model in breast cancer research. A team around biochemist Dr. Sonja Eberth and bioinformatician Dr. Claudia Pommerenke from the Leibniz Institute DSMZ-German ...
Medical artificial intelligence (AI) faces a fundamental challenge: uncertainty quantification. Artificial neural networks are largely unaware of the limits of their training data and can become ...
The typical timeline for subtyping influenza A specimens has sped up to help identify emerging avian flu cases in the United States, and an expert shares strategies for meeting the increased demand ...
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results